FUNDAMENTALS · Fundamentals · AU Healthcare

Telix Pharmaceuticals (TLX) Fundamentals 2026 — Revenue Analysis | SniperIQ

Telix Pharmaceuticals (TLX) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A$5.0B, trading at A

4.86 on the ASX. This SniperIQ fundamentals page covers Telix Pharmaceuticals's valuation, profitability (net margin -0.9%), revenue (A
.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapA$5.0B
Net Margin-0.9%
Revenue (FY25)A
.2B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Telix Pharmaceuticals's market cap?

Telix Pharmaceuticals (TLX) has a market capitalization of approximately A$5.0B, trading at A

4.86 on the ASX. Market cap moves with the live share price.

What is Telix Pharmaceuticals's P/E ratio?

Telix Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 8.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Telix Pharmaceuticals?

Telix Pharmaceuticals runs a net profit margin of -0.9%, a gross margin of 50.8%, and an operating margin of 2.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Telix Pharmaceuticals generate?

Telix Pharmaceuticals reported revenue of A

.2B for fiscal year 2025, with net income of -A
1M and earnings per share (EPS) of -0.0327. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Telix Pharmaceuticals pay a dividend?

Telix Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Telix Pharmaceuticals financially healthy?

Telix Pharmaceuticals carries a debt-to-equity ratio of 1.12x and a current ratio of 1.43x, with a market beta of 0.63. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Telix Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Telix Pharmaceuticals (TLX) the key facts are: market cap A$5.0B, revenue A

.2B, 52-week range 8.26-23.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Telix Pharmaceuticals's full fundamentals live

Get Telix Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Hangzhou Biotest Biotech (688767) fundamentals · Indivior Pharmaceuticals (INDV) fundamentals · Suzhou MedicalSystem Technology (603990) fundamentals · Sotera Health (SHC) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons